Dolezal, James M.
Wolk, Rachelle
Hieromnimon, Hanna M.
Howard, Frederick M.
Srisuwananukorn, Andrew http://orcid.org/0000-0002-8736-8726
Karpeyev, Dmitry
Ramesh, Siddhi
Kochanny, Sara
Kwon, Jung Woo
Agni, Meghana
Simon, Richard C.
Desai, Chandni
Kherallah, Raghad
Nguyen, Tung D.
Schulte, Jefree J. http://orcid.org/0000-0003-3920-0301
Cole, Kimberly
Khramtsova, Galina http://orcid.org/0000-0001-9625-1549
Garassino, Marina Chiara
Husain, Aliya N.
Li, Huihua
Grossman, Robert http://orcid.org/0000-0003-3741-5739
Cipriani, Nicole A.
Pearson, Alexander T. http://orcid.org/0000-0003-2801-7456
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01-CA243075)
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (R56-DE030958)
EIF | Stand Up To Cancer
EC | Horizon 2020 Framework Programme (SC1-BHC)
U.S. Department of Defense
Article History
Received: 13 January 2023
Accepted: 12 May 2023
First Online: 29 May 2023
Competing interests
: D.K. was employed by Ghost Autonomy, Inc. during the course of this study, but holds no competing interests for this work. A.T.P. reports personal fees from Prelude Therapeutics Advisory Board, personal fees from Elevar Advisory Board, personal fees from AbbVie consulting, and personal fees from Ayala Advisory Board, all outside of submitted work. All remaining authors report no competing interests.